The North America Ovulation Testing Kits Market would witness market growth of 5.7% CAGR during the forecast period (2023-2030). In the year 2019, the North America market's volume surged to 1,57,091.3 thousand units, showcasing a growth of 4.1% (2019-2022).
Vendors continuously invest in research and development to innovate and improve their ovulation testing products. This includes developing more accurate, user-friendly, and technologically advanced kits. Innovations include integrating digital technology, connectivity with smartphone apps, and enhanced accessibility. In addition, vendors need to constantly upgrade their products due to the growing competition based on affordability and the ability of ovulation test kits that provide mainly an accurate result from the home. To prevent unintentional pregnancies and ensure better healthcare for children, the market is expected to increase in the coming years. Geratherm Medical AG, Nectar Lifesciences Ltd, Philippine Blue Cross Biotech Corp, and Swiss Precision Diagnostics GmbH are among the most popular vendors.
Furthermore, the market is experiencing a growth in sales of home testing equipment and ongoing product development efforts. With easy access through e-commerce platforms, pharmacies, and brick-and-mortar retail outlets, there is a growing demand for home testing devices. Numerous companies are engaging in strategic partnerships to cater to the needs of women. For instance, in February 2019, NFI Consumer Healthcare extended its partnership with Callitas Health to distribute jointly branded products, including NFI's e.p.t Numeric, the top-the-counter (OTC) digital ovulation test kit in the United States.
The rising utilization of in vitro fertilization (IVF) treatments in Canada has contributed to the growth of the market in the country. Fertility clinics in Canada often recommend or require patients to use ovulation testing kits to ensure they are prepared for IVF treatments. Clinic recommendations drive the demand for these kits. And remote consultations have facilitated the use of ovulation testing kits for IVF treatments in Canada. Patients can share their ovulation data with healthcare providers without the necessity for frequent in-person visits. Ovulation testing kits are generally approved and recommended by regulatory authorities and healthcare professionals in Canada, further supporting their use in IVF treatments. These factors will expand the market growth in this region.
The US market dominated the North America Ovulation Testing Kits Market, by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $909 million by 2030. The Canada market is exhibiting a CAGR of 8.1% during (2023 - 2030). Additionally, The Mexico market would experience a CAGR of 7.1% during (2023 - 2030).
Based on Product, the market is segmented into Urine Ovulation Test, Digital Ovulation Test, and Saliva Ovulation Test. Based on Distribution Channel, the market is segmented into Pharmacies & Drugstores, Hypermarkets & Supermarkets, and E-Commerce. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Ovulation Testing Kits Market is Predict to reach $3.7 Billion by 2030, at a CAGR of 6.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include AccuQuik Testkits (AdvaCare Pharma), Fairhaven Health, LLC, Equinox Biotech Co., Ltd., Wondfo Biotech Co., Ltd, Pregmate, SPD Swiss Precision Diagnostics GmbH, Proov, Roman Health Ventures Inc. (Ro), Premom (Easy@Home Fertility), and Piramal Enterprises Limited.
By Product (Volume, Thousand Units, USD Million, 2019-2030)
By Distribution Channel (Volume, Thousand Units, USD Million, 2019-2030)
By Country (Volume, Thousand Units, USD Million, 2019-2030)
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
